EUR/USD 1.04767
0.087%
Gold 2938.22
-0.489%
Oil 71.001
0.258%
USD/JPY 149.760
0.022%
GBP/USD 1.26362
0.098%
GBP/JPY 189.243
0.142%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The head of Japans steel industry: As global protectionism grows, Japan should consider its trade policy from a new perspective.An executive at U.S. medical technology company Medtronic: (On the issue of U.S. tariffs) We are looking for ways to optimize our manufacturing layout.On February 25, people familiar with the matter said that Indonesia and Apple (AAPL.O) have reached an agreement to lift the countrys ban on iPhone16, paving the way for an end to a five-month tug-of-war that forced Apple to increase its promised investment in Indonesia to $1 billion. The Indonesian Ministry of Industry, which is responsible for maintaining the ban, will sign an agreement with Apple as early as this week. The two sides will also hold a press conference, and the Indonesian Ministry of Industry plans to issue a license allowing the sale of iPhone16 as soon as possible. People familiar with the matter added that in addition to the $1 billion investment, Apple will also be committed to training locals to work in the research and development of Apple products so that they can develop similar software and design their own products. The move is intended to appease the government, which has been pushing Apple to establish research and development facilities in the country. However, although both parties agreed to the terms of lifting the ban, Indonesia has previously reneged and the agreement may still fall through.On February 25, the DeepSeek API open platform showed that DeepSeek has reopened API recharge. The deepseek-chat model discount period has ended, and the call price has been changed to 2 yuan per million input tokens and 8 yuan per million output tokens. DeepSeek had previously stopped recharges due to resource constraints.On February 25, Morgan Stanley published a research report stating that due to the continued sales pressure of traditional drugs, it decided to further reduce the sales forecast of Shijiazhuang Pharmaceutical Group (01093.HK) by 2.1% in 2024; the sales forecast for 2025 was raised by 3.5%; and the sales forecast for 2026 was raised by 2.7%. Morgan Stanley mentioned that since Shijiazhuang Pharmaceutical attaches great importance to research and development, it has raised its forecast for its research and development expenses, which is partially offset by lower sales expenses. The bank adjusted its profit forecasts for fiscal years 2024 to 2026 by -14%, +10% and -4.3%, respectively. In addition, the bank lowered its capital expenditure forecast for Shijiazhuang Pharmaceutical in the next few years to 7% per year (originally 9%), and slightly raised its target price from HK$6.6 to HK$6.8, giving it an overweight rating.

$14.8 Billion Proposal From KKR-led Consortium Boosts Ramsay Health Care's Shares

Aria Thomas

Apr 20, 2022 10:00

q2.png


The non-binding offer price of A$88 in cash per share represents an almost 37% premium over Ramsay's Tuesday closing price of A$64.39. The offer boosted the hospital operator's shares by up to 29.8 percent to A$83.55 in early trading, the largest intraday gain in company history.


Ramsay said in a statement that it would undertake non-exclusive due diligence to the KKR-led group and that discussions were at an early stage.


The hospital operator said that it had evaluated the proposal with its advisors and requested further information from the partnership on the group's finances and deal structure.


KKR did not react quickly to a request for comment from Reuters.


If completed, the buyout would be the largest in Australia this year, almost doubling transaction activity, which fell 41.2 percent year on year in the first quarter to $17.4 billion, according to Refinitiv data.


The suggestion comes as record-low borrowing rates encourage private equity companies, superannuation funds, and pension funds to invest in healthcare and infrastructure assets.


Additionally, the transaction would be the largest private equity-backed takeover of an Australian corporation. The nation has seen a rush of spectacular takeovers in the last year, including the acquisition of Sydney Airport and Block Inc S acquisition of Afterpay, the buy-now-pay-later king.


The pandemic impacted healthcare operators such as Ramsay, with non-emergency procedures being closed, workforce shortages owing to isolation laws, and upward wage pressure impacting on profits, making the industry more inexpensive for a buyout than it was a few years ago.


CSL (OTC:CSLLY) Ltd, an Australian pharmaceutical company, announced last year that it will acquire Swiss manufacturer Vifor Pharma AG for $11.7 billion.


The transaction would provide a significant return for the Paul Ramsay Foundation, the company's largest shareholder at 18.8 percent.


Paul Ramsay founded the Foundation in 1964 with the conversion of a Sydney guest house into one of the country's first mental hospitals. In 2019, the Foundation sold approximately 11% of the firm for A$61.80 per share, much less than KKR's indicated price.


Reuters' request for comment was not immediately responded to.


According to its website, Ramsay runs hospitals and clinics in ten countries across three continents, with a network of more than 530 facilities.


It runs 72 private hospitals and day surgery centres in Australia and over 350 clinics and primary care units in six European countries.


KKR presently owns Elsan, a French healthcare company.


Earlier this year, IHH Healthcare Bhd made Ramsay and Malaysia's Sime Darby Holdings a $1.35 billion acquisition bid for their Asia joint venture. Ramsay said that it was continuing to pursue this purchase.


The hospital operator has retained UBS AG's Australia Branch and Herbert Smith Freehills as financial and legal consultants on the KKR-led consortium's bid, respectively.

Suggestion